When translated into the number of patients needing treatment, substituting semaglutide for other glucose-lowering agents would prevent one additional seizure for every 70 patients treated, and substituting semaglutide for SGLT2 inhibitors would prevent one additional seizure for every 131 patients treated
Tirzepatide users (Zepbound / Mounjaro) also reported shedding more often than placebo, but again the rates were modest
This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access 189,00 per year only 15,75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
This is because the impact on health budgets could be so great that the system cannot sustain it
Savale, L., Chaumais, M
[DOI] [PubMed] [Google Scholar] 14.Ma X., Liu Z., Ilyas I., Little P.J., Kamato D., Sahebka A., Chen Z., Luo S., Zheng X., Weng J., et al
